MID-VOLUME · DEATH-HEAVY
ranibizumab Side Effects
ranibizumab (also sold as Lucentis) sits MID-VOLUME #206 of 524 by FAERS report count. Lead signal: DEATH-HEAVY - 19.4% of FAERS reports list death as an outcome (5,072 of 26,174). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 26,174
- FAERS reports
FDA Adverse Event Reporting System extract for ranibizumab. Stamp set CASELOAD · DEATH-HEAVY · HOSP-MID. How figures are compiled.
ranibizumab: 19.4% of FAERS reports list death as an outcome (5,072 of 26,174). Caseload stamp CASELOAD; volume band MID-VOLUME #206 of 524 by FAERS report count.
Mid-book FAERS page for ranibizumab (Lucentis) (26,174 reports). Signature DEATH-HEAVY. Dominant age band on file: 75+. Educational reference only.
Counts from the openFDA FAERS extract (2005–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
DEATH leads 3,783 of 26,174 reports
Who reports · age peak 75+ (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 75+ (6,674 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (5,072 reports, 19.4%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 3,778 |
| MYOCARDIAL INFARCTION | 203 |
| CEREBROVASCULAR ACCIDENT | 172 |
| PNEUMONIA | 106 |
| VISUAL ACUITY REDUCED | 81 |
| FALL | 77 |
| CARDIAC FAILURE | 69 |
| CARDIAC ARREST | 67 |
| MYOCARDIAL ISCHAEMIA | 64 |
| ATRIAL FIBRILLATION | 57 |
| CARDIAC FAILURE CONGESTIVE | 57 |
| MALAISE | 54 |
| HYPERTENSION | 49 |
| NEOPLASM MALIGNANT | 42 |
| SEPSIS | 38 |
| RENAL FAILURE | 36 |
| BRONCHOPNEUMONIA | 35 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 33 |
| LUNG NEOPLASM MALIGNANT | 32 |
Reactions in Hospitalization Reports
Hospitalization mid-share (4,781, 18.3%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| CEREBROVASCULAR ACCIDENT | 567 |
| VISUAL ACUITY REDUCED | 398 |
| FALL | 337 |
| MYOCARDIAL INFARCTION | 319 |
| PNEUMONIA | 243 |
| MALAISE | 198 |
| VISUAL IMPAIRMENT | 198 |
| CEREBRAL INFARCTION | 192 |
| VISION BLURRED | 166 |
| ENDOPHTHALMITIS | 158 |
| EYE PAIN | 154 |
| TRANSIENT ISCHAEMIC ATTACK | 143 |
| HYPERTENSION | 142 |
| ATRIAL FIBRILLATION | 133 |
| DYSPNOEA | 133 |
| EYE HAEMORRHAGE | 127 |
| RETINAL HAEMORRHAGE | 125 |
| DEATH | 113 |
| BLINDNESS | 110 |
How to read ranibizumab FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-MID)
FAERS holds 26,174 voluntary reports linked to ranibizumab (Lucentis), 2005-2025. Death is listed on 5,072 (19.4%). Hospitalization appears on 4,781 (18.3%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 19.4% of FAERS reports list death as an outcome (5,072 of 26,174).
Read with ranibizumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 26,244 FAERS cases (Δ 70 heavier vs ranibizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 26,613 FAERS cases (Δ 439 heavier vs ranibizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 27,049 FAERS cases (Δ 875 heavier vs ranibizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 25,229 FAERS cases (Δ 945 lighter vs ranibizumab); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 42.7 pp vs ranibizumab's DEATH-HEAVY): CASELOAD · HOSP-MID.
ranibizumab stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.